Summary
32 / 100 · Bulios Score
What speaks for it
- Revenue grew by 98% a year over the last 3 years.
- Analysts expect revenue to grow by 14% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue grew by 199% a year over 5 years. Over the last 3 years it grew by 98% a year. For the next fiscal year analysts expect revenue to grow by 14%.
Growth in detailDoes it make money?
PoorlyWhere 100 AUD of revenue goes
- Cost of sales 48 AUD
- Research and development 24 AUD
- Sales and administration 29 AUD
- Taxes and other -4.3 AUD
- Net profit 3.6 AUD
Net profit, industry median (Biotechnology) -7.3 AUD
Out of every 100 AUD of revenue, 3.6 AUD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Today's price within the analysts' price targets
The average target of $20 is 119% above today's price.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 99%
- CHINA 1.2%
UNITED STATES brings in 99% of revenue.
Segments in detail